CagriSema Dosage Chart: Weekly Titration, Doses, and Trial Results

CagriSema is dosed once weekly as a subcutaneous injection that combines equal milligrams of cagrilintide and semaglutide. Treatment typically starts at 0.25 mg of each component and steps up about every four weeks until it reaches the 2.4 mg/2.4 mg maintenance dose studied in phase 3 trials. CagriSema is still investigational and is not FDA-approved for weight loss or any other use in the United States.

CagriSema Components and How the Dose Is Written

CagriSema is a single product built from two active ingredients, which is why a dosage chart can look confusing at first glance.

• Cagrilintide — a long-acting amylin analog that slows gastric emptying and increases satiety.
• Semaglutide — a GLP-1 receptor agonist, the same molecule used in Ozempic and Wegovy.

Both components move in lockstep at the same milligram amount. A "2.4 mg" CagriSema dose means 2.4 mg of cagrilintide plus 2.4 mg of semaglutide, for 4.8 mg of active drug per injection. When a chart lists only one number, it is describing each individual component rather than the total.

CagriSema Dosage Chart: Weekly Titration Steps

The schedule below reflects the four-week escalation used in REDEFINE-1, the phase 3 trial in adults with obesity or overweight. Investigators could slow the climb if gastrointestinal side effects became difficult to manage.

Treatment week	Cagrilintide	Semaglutide	Total per injection
Weeks 1–4	0.25 mg	0.25 mg	0.5 mg
Weeks 5–8	0.5 mg	0.5 mg	1.0 mg
Weeks 9–12	1.0 mg	1.0 mg	2.0 mg
Weeks 13–16	1.7 mg	1.7 mg	3.4 mg
Week 17 and later	2.4 mg	2.4 mg	4.8 mg

Each dose is injected subcutaneously once per week, ideally on the same day. In the trial protocols, a missed dose was generally taken within a defined window; past that window, participants resumed the next scheduled dose instead of doubling up.

Reaching 2.4 mg/2.4 mg is a target, not a requirement. Some participants stayed at a lower maintenance dose and still lost weight, a pattern also seen with other GLP-1-based therapies.

CagriSema Dosage for Weight Loss: What the Trials Showed

In REDEFINE-1, participants who reached the 2.4 mg/2.4 mg dose lost an average of 22.7% of their body weight at 68 weeks. The same trial reported average losses of about 16.1% with semaglutide 2.4 mg alone and 11.8% with cagrilintide 2.4 mg alone.

Treatment (68 weeks)	Average weight loss
CagriSema 2.4 mg / 2.4 mg	22.7%
Semaglutide 2.4 mg	16.1%
Cagrilintide 2.4 mg	11.8%

REDEFINE-2, which enrolled people with type 2 diabetes, reported meaningful blood sugar reductions along with weight loss. These are averages from specific trial populations, so individual results vary widely.

Gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation were the most common reasons people reduced or stopped treatment. Most of these effects clustered during the titration phase and eased as the dose stabilized.

CagriSema has not been approved by the FDA, so any real-world dosing guidance comes from a clinical trial protocol or a prescriber's judgment, not from an approved product label.

Is There a CagriSema 10 mg Dose?

No. The CagriSema program has not studied a 10 mg dose of either component, and no 10 mg strength exists in the published trial data.

Searches for "cagrisema 10mg" usually trace back to one of three things:

1. Compounded semaglutide sold in 10 mg vials, which is a different product.
2. Unrelated research peptides that are commonly shipped as 10 mg vials.
3. A misreading of the 1.0 mg titration step in the chart above.

Any vendor advertising a 10 mg CagriSema pen or vial is making a claim that does not match the research. Unapproved and compounded products can also vary in purity and actual content.

Other Peptide Dosing Schedules People Compare

Dose charts are not interchangeable between compounds, even when the injection route is the same. A growth hormone secretagogue stack such as sermorelin ipamorelin cjc1295 dosage follows an entirely different rhythm from a GLP-1 and amylin combination, and metabolic peptides studied for fat loss, like aod-9604 5mg dosage, are dosed on their own timelines.

Researchers also frequently look up l carnitine injection dosage for body composition work, pt 141 dosage for men in libido studies, and epitalon dosage injection in longevity research. Each of those protocols reflects a different mechanism, half-life, and safety profile. None of them can be substituted for CagriSema dosing.

Safety and Monitoring

CagriSema combines two drugs that each carry their own cautions, so medical supervision matters.

• Gastrointestinal: nausea, vomiting, diarrhea, and constipation are the most frequent side effects.
• Gallbladder and pancreas: gallstones and pancreatitis have been reported with GLP-1-based therapies.
• Thyroid: semaglutide carries a boxed warning about thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN2.
• Pregnancy: GLP-1 and amylin-based drugs are not intended for use during pregnancy, and stopping before conception is usually advised.

CagriSema is not a cure for obesity or diabetes, and it is not a substitute for diet, activity, or prescribed diabetes care. Anyone considering it should talk with a licensed healthcare professional about eligibility, monitoring, and interactions with other medications.

Bottom Line

The CagriSema dosage chart runs from 0.25 mg of cagrilintide and semaglutide per week to a maintenance dose of 2.4 mg of each, escalated in four-week steps. That schedule comes from phase 3 research rather than an approved label, and no 10 mg version exists. Because the drug remains investigational, dosing decisions belong with a qualified clinician, not a chart alone.

COMMON QUESTIONS

Frequently Asked Questions

What is the starting dose of CagriSema?

CagriSema starts at 0.25 mg of cagrilintide plus 0.25 mg of semaglutide, injected subcutaneously once weekly. The dose then increases roughly every four weeks, following the same escalation used in the REDEFINE-1 phase 3 trial.

Is CagriSema FDA-approved in the United States?

No. CagriSema is an investigational drug and has not been approved by the FDA for weight loss, diabetes, or any other indication. It is only legally available to participants enrolled in clinical trials or through expanded access programs.

Is there a 10 mg CagriSema dose or pill?

There is no 10 mg CagriSema dose and no CagriSema pill. The highest dose studied in trials is 2.4 mg of cagrilintide plus 2.4 mg of semaglutide per weekly injection, and the product is injectable only.